+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 18Years +
All Genders
ID07044232

Study of Nicardipine Infusion Versus Glyceryl Trinitrate Patch for Rapid Blood Pressure Control in Adults with Acute Intracerebral Hemorrhage

Led by Aarhus University Hospital · Updated on 2026-06-24

88

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a new treatment approach for people who have experienced spontaneous intracerebral hemorrhage ICH, a serious type of stroke where bleeding occurs within the brain. The study aims to compare a treatment method that prioritizes intravenous antihypertensive drugs, such as nicardipine, against the traditional use of long-acting nitrate patches. This study is designed to see if the new approach can help more patients reach a safer systolic blood pressure level below 140 mmHg within one hour of hospital admission while keeping track of safety and clinical outcomes. Participants will receive one of two treatment plans during the acute phase of ICH. One group will receive an infusion of nicardipine at 5 mghour with lower doses for certain patients along with other possible medications like labetalol and methyldopa, while the other group will receive glyceryl trinitrate patches combined with labetalol and nimotope. Both treatments are given for less than 72 hours. The study involves a stepwise rollout of the nicardipine-based protocol at the hospital, with careful monitoring of blood pressure control and resource use. During the study, participants will be closely monitored for blood pressure levels shortly after admission and for functional outcomes over several months. Researchers will track serious adverse events, kidney injury, consciousness levels, intensive care use, neurosurgery, mortality, and blood pressure readings at multiple time points after treatment starts. The main outcome is the proportion of patients achieving the target blood pressure within one hour. Participants may be followed for up to six months to assess various health outcomes and hospital resource use.

CONDITIONS

Brief Title

NICardipine for Fast Achievement of Systolic BP Targets in ICH

Research Team

R

Rolf Blauenfeldt, MD, PhD

C

Claus Z Simonsen, MD, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here